Pentixapharm Holding (FSE: PTP)

Last close As at 05/08/2026

EUR1.93

0.05 (2.39%)

Market capitalisation

EUR48m

Pentixapharm is a Germany-based clinical-stage radiopharmaceutical company focused on developing CXCR4-targeted theranostic agents for cancer, cardiovascular and inflammatory diseases. Its lead programmes, PentixaFor (diagnostic) and PentixaTher (therapeutic), leverage a validated peptide platform, with PentixaFor currently in Phase III development in primary aldosteronism.

Market Data

Share Price EUR1.93
Market Cap EUR48m
52-Week High EUR3.52
52-Week Low EUR1.26
% Change 1M (8.1)
% Change 6M 10.4
% Change 12M 4.0
Ave. Daily Volume 1yr 494

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Dr. Dirk Pleimes

    Group CEO & CMO

  • Dr. Erik Merten

    CTO

Share Price Chart

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.